Marinus Pharmaceuticals Inc (MRNS) : Canaan Partners Vii has sold out all of its stake in Marinus Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Oct 7, 2016 with the SEC. The investment management company has sold out 2,461,399 shares of Marinus Pharmaceuticals Inc which is valued at $3,741,326.
Marinus Pharmaceuticals Inc closed down -0.05 points or -3.18% at $1.52 with 5,11,858 shares getting traded on Friday. Post opening the session at $1.59, the shares hit an intraday low of $1.48 and an intraday high of $1.6 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Many Wall Street Analysts have commented on Marinus Pharmaceuticals Inc. Company shares were Reiterated by Jefferies on Aug 10, 2016 to “Buy”, Firm has raised the Price Target to $ 3 from a previous price target of $2.50 .
Marinus Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate ganaxolone is a small molecule that is a synthetic analog of allopregnanolone which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Company’s indication for ganaxolone is as an adjunctive or add-on therapy for the treatment of partial also known as focal onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Company’s oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.